User profiles for Aliccia Bollig-Fischer

Aliccia Bollig-Fischer

Wayne State University, Barbara Ann Karmanos Cancer Institute
Verified email at med.wayne.edu
Cited by 2652

Genomic amplification and oncogenic properties of the GASC1 histone demethylase gene in breast cancer

G Liu, A Bollig-Fischer, B Kreike, MJ van de Vijver… - Oncogene, 2009 - nature.com
Earlier, mapping of the 9p23–24 amplicon in esophageal cancer cell lines led us to the
positional cloning of gene amplified in squamous cell carcinoma 1 (GASC1), which encodes a …

Genes associated with prostate cancer are differentially expressed in African American and European American men

…, CN Giroux, AG Schwartz, A Bollig-Fischer - … , biomarkers & prevention, 2013 - AACR
Background: Despite more aggressive screening across all demographics and gradual
declines in mortality related to prostate cancer (PCa) in the United States, disparities among …

Two members of the TRiC chaperonin complex, CCT2 and TCP1 are essential for survival of breast cancer cells and are linked to driving oncogenes

ST Guest, ZR Kratche, A Bollig-Fischer… - Experimental cell …, 2015 - Elsevier
Gene amplification is a common mechanism of oncogene activation in cancer. Several large-scale
efforts aimed at identifying the comprehensive set of genomic regions that are …

Transforming properties of 8p11-12 amplified genes in human breast cancer

ZQ Yang, G Liu, A Bollig-Fischer, CN Giroux, SP Ethier - Cancer research, 2010 - AACR
Amplification of the 8p11-12 region has been found in about 15% of human breast cancers
and is associated with poor prognosis. Earlier, we used genomic analysis of copy number …

[HTML][HTML] Functional role of miR-10b in tamoxifen resistance of ER-positive breast cancer cells through down-regulation of HDAC4

A Ahmad, KR Ginnebaugh, S Yin, A Bollig-Fischer… - BMC cancer, 2015 - Springer
Background For breast cancer patients diagnosed with estrogen receptor (ER)-positive tumors,
treatment with tamoxifen is the gold standard. A significant number of patients, however, …

Minireview: the molecular and genomic basis for prostate cancer health disparities

IJ Powell, A Bollig-Fischer - Molecular endocrinology, 2013 - academic.oup.com
Despite more aggressive screening across all demographics and gradual declines in mortality
related to prostate cancer (PCa) in the United States, race disparities persist. For African …

[HTML][HTML] Intronic non-CG DNA hydroxymethylation and alternative mRNA splicing in honey bees

…, CC Chen, M Coon, A Sammak, A Bollig-Fischer… - BMC genomics, 2013 - Springer
Background Previous whole-genome shotgun bisulfite sequencing experiments showed
that DNA cytosine methylation in the honey bee (Apis mellifera) is almost exclusively at CG …

[HTML][HTML] Treating triple negative breast cancer cells with erlotinib plus a select antioxidant overcomes drug resistance by targeting cancer cell heterogeneity

…, G Dyson, SR Terlecky, A Bollig-Fischer - Scientific reports, 2017 - nature.com
Among breast cancer patients, those diagnosed with the triple-negative breast cancer (TNBC)
subtype have the worst prog-nosis. TNBC does not express estrogen receptor-alpha, …

Racial disparities in the molecular landscape of cancer

…, SK Reddy, E Obeid, SV Liu, A Bollig-Fischer… - Anticancer …, 2018 - ar.iiarjournals.org
Background/Aim: African Americans (AA) have the highest incidence and mortality of any
racial/ethnic group in the US for most cancer types. Heterogeneity in the molecular biology of …

[HTML][HTML] Hyperglycemia and O-GlcNAc transferase activity drive a cancer stem cell pathway in triple-negative breast cancer

…, EA Teslow, LA Polin, G Dyson, A Bollig-Fischer… - Cancer Cell …, 2023 - Springer
Background Enhanced glucose metabolism is a feature of most tumors, but downstream
functional effects of aberrant glucose flux are difficult to mechanistically determine. Metabolic …